Sanofi Scouting For Cancer Deals, Diabetes Drugs Miss In 1Q
Executive Summary
Sanofi is seeking asset deals to bulk up its oncology pipeline in 2017 – specifically, the big pharma is on the lookout for oncology compounds with potential in prostate cancer or breast cancer, the company highlighted during its first-quarter earnings call.
You may also be interested in...
PCSK9 Sponsors Still Face Challenges In Turning Around Dismal Launches
After reporting yet another quarter of disappointing sales, Amgen and Sanofi/Regeneron look forward to better performance now that outcomes data are out, but payers may not be up for easing hurdles enough.
Deal Watch: Seattle Genetics' Controversial Collaboration With Immunomedics Topples
A licensing deal between the two cancer-focused biotechs falls apart amidst investor unrest at Immunomedics. Novartis opts to license Conatus' Phase II NASH candidate and picks up a CAR-T candidate from Celyad, while Shire adds to its dry eye franchise in deal with Parion.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.